7th National Formulary of India (Health)
7th National Formulary of India (Health)
Why In News:
The Indian Pharmacopoeia Commission (IPC) launched the 7th edition of the National Formulary of India (NFI-2026) on 21 September 2026, along with new initiatives to strengthen pharmacovigilance, materiovigilance and biovigilance in India.
National Formulary of India (NFI-2026)
NFI is an official reference document that promotes the rational, safe and evidence-based use of medicines by healthcare professionals.
It provides information on medicines, therapeutic uses, dosage, precautions and appropriate prescribing, helping reduce irrational medication use.
The Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health and Family Welfare, publishes the NFI.
The 7th edition, NFI-2026, contains 34 chapters, 20 appendices and information on 653 medicines, including 42 fixed-dose combinations and 30 immunological medicines.
Its drug monographs have been aligned with the National List of Essential Medicines (NLEM) and national health programmes.
NFI and Indian Pharmacopoeia (IP) are different:
Indian Pharmacopoeia (IP): Specifies official quality standards such as identity, purity and strength of medicines.
National Formulary of India (NFI): Guides their rational and safe clinical use.
India’s Pharmacovigilance Framework
Pharmacovigilance Programme of India (PvPI): A national system for detecting, assessing and monitoring adverse drug reactions (ADRs) and other medicine-related safety problems.
Materiovigilance Programme of India (MvPI): Monitors adverse events associated with medical devices, making it distinct from PvPI, which primarily concerns medicines.
Biovigilance Programme of India: The Government has approved a dedicated programme to monitor adverse events associated with organ and tissue transplantation, thereby widening India’s patient-safety surveillance framework.
Key Facts for Prelims
Indian Pharmacopoeia Commission (IPC): Based in Ghaziabad, it is responsible for the publication of the Indian Pharmacopoeia and plays a central role in India’s pharmacovigilance system.
CDSCO: The Central Drugs Standard Control Organisation is India’s central drug regulatory authority; safety signals generated through PvPI can support regulatory action by CDSCO.
NLEM: The National List of Essential Medicines identifies medicines considered necessary for priority healthcare needs and is periodically revised by the Ministry of Health and Family Welfare.
National Pharmacovigilance Week 2026: The 6th edition was observed from 17–23 September 2026, with the theme focusing on rational use of medicines and safer healthcare.